## 1 Supplement

### 2 eMethods

### 3 PET-based staging systems

PET-based staging systems were included as non-binary categorical measures
of Aβ and tau pathology. We included two systems for Aβ: a three-stage system
developed by Mattsson et al<sup>1</sup> and a four-stage system developed by Collij et al<sup>2</sup>. We
included Braak staging for tau<sup>3,4</sup>, including both a three-stage and six-stage version.
Each stage in each system was associated with a collection of Freesurfer ROIs (stage
composite), as shown in eTable 2, with advancing stages indicating regions where
pathology spreads over the disease course.

11 The method for Mattsson staging and Braak staging were similar and proceeded 12 as follows. First, an average SUVR was calculated in each stage composite using a 13 volume weighted average of bilateral regions. Next, Gaussian mixture models (GMM) 14 were fit to the distribution of uptake in each stage composite to estimate a binary cutoff 15 for stage positivity (as described in the main text Methods: Image-based biomarker 16 definitions). These cutoffs allowed us to assign binary positivity measures for each 17 subject in each stage composite. Disease stages were then assigned based on 18 individual patterns of positivity: to be assigned a given disease stage, an individual had 19 to exhibit positivity for that stage and all prior ones. In case an individual was positive 20 for a given stage but not all prior stages, they were marked as non-stageable. 21 Individuals could also be assigned stage 0 if they were not positive for pathology in any 22 stage composite.

Collij staging was slightly different in that positivity for a stage composite was
based on being positive for pathology in most ROIs corresponding to a given stage.
That is, GMMs were fit to each Freesurfer ROI individually, and positivity for a stage
composite was defined by exhibiting supra-threshold uptake in 50% or more of the

associated ROIs. Disease stage assignment then proceeded in the same manner as
for Mattsson and Braak staging (individuals needed to be positive for a given disease
stage and all prior stages).

#### 30 Cross-validation experiments

Cross-validated modeling was implemented in Python (v3.10) using scikit-learn (v1.4.2). For all cross-validation experiments, CDR status was used as a stratifying variable. Random samples were also seeded, such that the individuals of each testing fold were the same across experiments with the same input data. All cross-validation experiments had 10 outer folds and were repeated 10 times to generate 100 out of sample error estimates for each tested model.

37 We first ran models for each biomarker separately to assess the predictive value 38 of each included definition. These experiments used a non-nested, 10-fold cross-39 validation. In each iteration, training data were used to fit linear regressions where 40 PHC<sub>Global</sub> was predicted from a single biomarker and covariates (age, sex, APOE E4 41 positivity). That is, separate models were fit for each biomarker. Biomarker definitions 42 with tunable parameters (Z-scores, GMMs) were also fit with training data. A baseline 43 model was also trained in each iteration which only included covariates as predictors. 44 Trained models were then evaluated on the testing fold data, and the prediction 45 accuracies for each were calculated as root mean squared error (RMSE).

46 We next created combinatorial models to test if combination of biomarkers improved prediction accuracy and if models incorporating continuous or non-categorical 47 48 binary biomarkers outperformed models with binary biomarkers. For these 49 experiments, we used nested cross-validation with 10 outer folds and 5 inner folds. In 50 the inner cross-validation, a model selection procedure was applied to identify the best 51 performing individual predictors (like the non-nested cross-validation experiment 52 described above). Inner training data were used to fit linear models predicting PHC<sub>Global</sub> 53 with single biomarkers plus covariates as predictors. Inner testing data were used to 54 measure the out-of-sample accuracy of these models. We then grouped the models based on the pathology (AT(N)) and variable type (binary/non-binary 55

categorical/continuous) and selected the best performing biomarker definitions (lowest
average RMSE across 5 test folds). The outer cross-validation was then used for
training new linear models which combined the biomarkers selected from the inner
cross-validation. eTable 3 shows all the combinatorial linear models that were
evaluated in the outer loop using this training scheme.

61 We also used support vector machine (SVM) regression to directly predict 62 PHC<sub>Global</sub> from imaging data. SVMs were trained using regional A $\beta$  uptakes, tau 63 uptakes, or gray matter volumes as input features. An additional model combined all 64 these regional imaging features into a multimodal predictive model. SVM training used 65 a nested cross-validation design with 10 outer folds and 5 inner folds. The inner loop 66 was used for hyperparameter tuning for the regularization parameter C, the kernel, and 67 the kernel coefficient  $\gamma$ . Search spaces were informed by consensus recommendations<sup>5</sup> and from pilot experiments: kernel (linear or radial basis function 68 [RBF]), C with linear kernel  $(2^{-10}, 2^{-9}, \dots, 2^{-1}, 2^0)$ , C with RBF kernel 69

70  $(2^{-5}, 2^{-3}, \dots, 2^{13}, 2^{15}), \gamma$  with RBF kernel  $(2^{-15}, 2^{-13}, \dots, 2^{1}, 2^{3})$ . The best

71 hyperparameters were determined from the inner loop (lowest average RMSE across 5

test folds) and used to retrain and evaluate SVM models in the outer loop.

#### 73 Feature importance analyses

74 We ran additional post-hoc analyses to probe feature importance for our cross-75 validated linear modeling. For models which applied a model selection to filter 76 biomarker definitions, we created pie charts showing the specific biomarker definitions 77 which were selected as the best performing over repeated cross-validation iterations. 78 We also extracted and plotted the (standardized) linear model coefficients for the A $\beta$ , 79 tau, and neurodegeneration biomarkers in all binary and all continuous models (non-80 binary categorical models were omitted because coefficient interpretation is less 81 straightforward for non-binary categorical features). Finally, we visualized the cutoff 82 values that were selected for A $\beta$  and tau from models with all binary definitions.

For SVM models, we visualized the feature importance of individual brain regions
 for Aβ, tau, and neurodegeneration features. Following previous work<sup>6,7</sup>, feature

85 importance values were generated by calculating the covariance of each feature and

86 PHC<sub>Global</sub>. We generated brain maps showing the average feature importance across

87 100 out-of-sample model predictions. Maps were generated for the combined SVM and

88 for each unimodal SVM.

# 90 eTables

Name	Pathology	Variable type	Description	
Aβ composite	Αβ	Continuous	A $\beta$ SUVR in summary composite region	
Centiloid	Αβ	Continuous	Linear transformation of A $\beta$ composite SUVR <sup>8</sup>	
Aβ SUVR>1.11	Αβ	Binary	Cutoff from Landau et al. <sup>9</sup>	
Aβ SUVR>1.24	Αβ	Binary	Cutoff from Su et al. <sup>10</sup>	
Aβ SUVR>1.42	Αβ	Binary	Cutoff from Jack et al. <sup>11</sup> (reliable worsening)	
Aβ SUVR>1.30	Αβ	Binary	Cutoff from Jack et al. <sup>11</sup> (specificity)	
Centiloid>15	Αβ	Binary	Binary cutoff for Centiloid	
Centiloid>20	Αβ	Binary	Binary cutoff for Centiloid	
Centiloid>25	Αβ	Binary	Binary cutoff for Centiloid	
Centiloid>30	Αβ	Binary	Binary cutoff for Centiloid	
Aβ composite (GMM)	Αβ	Binary	$A\beta$ composite SUVR binarized with a GMM	
Aβ composite (z>2.0)	Αβ	Binary	Z-score cutoff of 2 for A $\beta$ composite SUVR	
Aβ composite (z>2.5)	Αβ	Binary	Z-score cutoff of 2.5 for A $\beta$ composite SUVR	
Aβ composite (Quartiles)	Αβ	Non-binary categorical	Quartiles of the A $\beta$ composite SUVR	
Centiloid (Quartiles)	Αβ	Non-binary categorical	Quartiles of Centiloid	
Mattsson staging	Αβ	Non-binary categorical	A $\beta$ –PET staging system <sup>2</sup>	
Collij staging	Αβ	Non-binary categorical	A $\beta$ –PET staging system <sup>1</sup>	
Aβ composite (BIZ)	Αβ	Non-binary categorical	Binarization with an intermediate zone for $A\beta$ composite	
Centiloid (BIZ)	Αβ	Non-binary categorical	Binarization with an intermediate zone for Centiloid	
MT tau SUVR	Tau	Continuous	Tau SUVR in meta-temporal composite region	
Braak I SUVR	Tau	Continuous	Tau SUVR in Braak I composite region	
Braak III/IV SUVR	Tau	Continuous	Tau SUVR in Braak III/IV composite region	
Braak V/VI SUVR	Tau	Continuous	Tau SUVR in Braak V/VI composite region	
MT tau (GMM)	Tau	Binary	Meta-temporal tau SUVR binarized with a GMM	
MT tau (z>2.0)	Tau	Binary	Z-score cutoff of 2 for MT tau SUVR	
MT tau (z>2.5)	Tau	Binary	Z-score cutoff of 2.5 for MT tau SUVR	
Tau SUVR>1.20	Tau	Binary	Cutoff from Jack et al. <sup>11</sup> (sensitivity)	
Tau SUVR>1.21	Tau	Binary	Cutoff from Jack et al. <sup>11</sup> (specificity)	
Tau SUVR>1.23	Tau	Binary	Cutoff from Jack et al. <sup>11</sup> (accuracy-young)	
Tau SUVR>1.33	Tau	Binary	Cutoff from Jack et al. <sup>11</sup> (accuracy-matched)	
MT tau (Quartiles)	Tau	Non-binary categorical	Quartiles of MT tau SUVR	
MT tau (BIZ)	Tau	Non-binary categorical	Binarization with an intermediate zone for MT tau SUVR	

Braak staging (3)	Tau	Non-binary categorical	Braak staging based on 3 stage model (I, III/IV, V/VI)
Braak staging (3)	Tau	Non-binary categorical	Braak staging based on 6 stage model (I, III, V, V, VI)
Hippocampus	Neurodegen.	Continuous	Hippocampal volume
MT volume	Neurodegen.	Continuous	Volume of the MT composite region
Hippocampus (z<-2.0)	Neurodegen.	Binary	Z-score cutoff of 2.0 for hippocampal volume
Hippocampus (z<-2.5)	Neurodegen.	Binary	Z-score cutoff of 2.5 for hippocampal volume
MT volume (z<-2.0)	Neurodegen.	Binary	Z-score cutoff of 2.0 for MT volume
MT volume (z<-2.5)	Neurodegen.	Binary	Z-score cutoff of 2.5 for MT volume
Hippocampus (Quartiles)	Neurodegen.	Non-binary categorical	Quartiles of hippocampal volume
MT volume (Quartiles)	Neurodegen.	Non-binary categorical	Quartiles of MT volume

**eTable 1.** Listing of all image-based AT(N) biomarkers used in cognitive prediction 92 models.

- 92 mode

- ...

Name	Citation	Regions
Aβ composite	12,13	caudal middle frontal, lateral orbitofrontal, medial orbitofrontal, pars opercularis,
		pars orbitalis, pars triangularis, rostral middle frontal, superior frontal, frontal pole,
		caudal anterior cingulate, isthmus cingulate, posterior cingulate, rostral anterior
		cingulate, inferior parietal, precuneus, superior parietal, supramarginal, inferior
		temporal, middle temporal, superior temporal
MT	11	entorhinal, amygdala, fusiform, inferior temporal, middle temporal
Braak I	14,15	entorhinal
Braak III		parahippocampal, fusiform, lingual, amygdala
Braak IV		middle temporal, caudal anterior cingulate, rostral anterior cingulate, posterior
		cingulate, isthmus cingulate, insula, inferior temporal, temporal pole
Braak V		superior frontal, lateral orbitofrontal, medial orbitofrontal, frontal pole, caudal
		middle frontal, rostral middle frontal, pars opercularis, pars orbitalis, pars
		triangularis, lateral occipital, supramarginal, inferior parietal, superior temporal,
		superior parietal, precuneus, bank of the superior temporal sulcus, transverse
		temporal
Braak VI		pericalcarine, postcentral, cuneus, precentral, paracentral
Mattsson Early	1	precuneus, posterior cingulate, isthmus cingulate, insula, medial orbitofrontal,
Mattecon		hank SSTS, caudal middle frontal, cupous, frontal polo, fusiform, inferior pariotal
Intermediate		inferior temporal lateral occipital middle temporal parahippocampal pars
Internetiate		opercularis, pas orbitalis, pars triangularis, putamen, rostral anterior cingulate
		rostral middle frontal, supramarginal
Mattsson Late		lingual, pericalcarine, paracentral, precentral, postcentral
Colllij 1	2	posterior cingulate, isthmus cingulate, anterior cingulate (caudal+rostral)
Collij 2		lateral orbitofrontal, paracentral, precuneus, medial orbitofrontal, inferior frontal
-		(pars opercularis+pas orbitalis+pars triangularis)
Collij 3		insula, fusiform, precentral, inferior temporal, parahippocampal, collijinferiorfrontal,
		superior frontal, lingual, supramarginal, inferior parietal, cuneus, middle frontal
		(rostral+caudal)
Collij 4		lateral occipital, superior parietal, middle temporal, superior temporal, postcentral,
		entorhinal, frontal pole, temporal pole

**eTable 2.** List of Freesurfer regions used for composite regions. Citations are included
 for papers which defined these composites. For Collij stging composites, regions

110 shown joined by plus signs are meta-ROIs constructed prior to averaging for the

111 composite, as described in the original paper<sup>2</sup>.  $A\beta$ =amyloid-beta, MT=meta-temporal,

112 ROI=region of interest.

...

Model	Αβ	Tau	Neurodegen	
Baseline	-	-	-	
A <sub>BIN</sub>	Binary	-	-	
T <sub>BIN</sub>	-	Binary	-	
N <sub>BIN</sub>	-	-	Binary	
A <sub>CAT</sub>	Non-binary categorical	-	-	
T <sub>CAT</sub>	-	Non-binary categorical	-	
N <sub>CAT</sub>	-	-	Non-binary categorical	
A <sub>CON</sub>	Continuous	-	-	
T <sub>CON</sub>	-	Continuous	-	
N <sub>CON</sub>	-	-	Continuous	
$A_{BIN}/T_{BIN}/N_{BIN}$	Binary	Binary	Binary	
A <sub>CAT</sub> /T <sub>CAT</sub> /N <sub>CAT</sub>	Non-binary categorical	Non-binary categorical	Non-binary categorical	
A <sub>CON</sub> /T <sub>CON</sub> /N <sub>CON</sub>	Continuous	Continuous	Continuous	
$A_{CAT}/T_{BIN}/N_{BIN}$	Non-binary categorical	Binary	Binary	
A <sub>BIN</sub> /T <sub>CAT</sub> /N <sub>BIN</sub>	Binary	Non-binary categorical	Binary	
$A_{BIN}/T_{BIN}/N_{CAT}$	Binary	Binary	Non-binary categorical	
A <sub>CON</sub> /T <sub>BIN</sub> /N <sub>BIN</sub>	Continuous	Binary	Binary	
$A_{BIN}/T_{CON}/N_{BIN}$	Binary	Continuous	Binary	
A <sub>BIN</sub> /T <sub>BIN</sub> /N <sub>CON</sub>	Binary	Binary	Continuous	

**eTable 3.** List of linear models predicting PHC<sub>Global</sub> from AT(N) biomarkers. Models

124 were trained with a nested-cross validation scheme where the inner loop was used to

select the best performing biomarkers, after grouping by pathology (A $\beta$ , tau,

neurodegeneration) and variable type. BIN, CAT, and CON are used to represent

127 binary, non-binary categorical, and continuous variables (respectively). Dashes are

shown to indicate omission of the corresponding biomarker in the model. All models

also had age, sex, and *APOE* E4 status included as covariates.

	CDR=0.0	CDR=0.5	CDR=1.0+	p-value
n	223	130	30	
Age	73.76 (7.07)	75.73 (8.32)	77.78 (8.48)	0.005
Sex (M/F)	96/127	75/55	16/14	0.026
APOE E4+	<u>79 (35.4%)</u>	45 (34.6%)	13 (43.3%)	0.659
Centiloid	19.92 (35.65)	41.74 (54.70)	69.79 (48.77)	<0.001
•Table 4: Char	oteristics for the su	ubsample with long	itudinal cognitive f	
				onowup.

	CDR=0.0	CDR=0.5	CDR=1.0+	p-value
n	143	83	20	
Age	73.29 (7.50)	74.26 (8.31)	75.91 (9.34)	0.322
Sex (M/F)	59/94	54/29	10/10	0.003
APOE E4+	49 (34.3%)	29 (34.9%)	12 (60.0%)	0.076
Centiloid	19.94 (38.52)	45.26 (55.40)	74.68 (48.25)	<0.001
PHC <sub>Global</sub>	0.87 (0.35)	0.32 (0.50)	-0.27 (0.53)	<0.001

eTable 5: Characteristics for the subsample with imaging and CSF biomarker

166 167 assessments.

168

### 170 eFigures



171

172 eFigure 1: Comparison of partial volume corrected (PVC) and non-PVC tau predictors 173 for modeling cognition. A. Boxplots of cross-validated accuracy (RMSE) for models 174 including a single tau predictor and covariates. **B.** Boxplots of cross-validated accuracy 175 (RMSE) for models with the best selected tau predictors. Solid colors indicate models 176 without tau PVC, while hatches indicate models with tau PVC. In both panels, the 177 baseline model (just covariates) is shown in gray, with the dotted line indicating its mean 178 performance. Gold stars indicate a significant improvement in accuracy relative to the 179 baseline model (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001). No significant differences were found 180 for comparisons of PVC and non-PVC models (all p>0.05).

181



**eFigure 2:** Regional weights for SVM models which included only A $\beta$  (**A**, A<sub>SVM</sub>), tau (**B**, 185 T<sub>SVM</sub>), or gray matter volume (**C**, N<sub>SVM</sub>).

- -



eFigure 3: Boxplots showing cross-validated accuracy (RMSE) measures for predicting PHC<sub>Global</sub> in CU (A) and CI (B) individuals. Individual and combination biomarker models are compared against a baseline model using only covariates (mean performance indicated by dotted line) to predict PHC<sub>Global</sub>. Colors are used to indicate the variable type of included biomarkers (yellow: binary, purple: non-binary categorical, red: continuous, blue: SVM). Lighter coloring indicates models which only have a single pathology assessment, while darker coloring indicates models which have A $\beta$ , tau, and neurodegeneration biomarkers. Gold stars indicate a significant improvement in accuracy relative to the baseline model (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001). 



eFigure 4: Boxplots showing cross-validated accuracy (RMSE) measures for predicting PHC<sub>Global</sub> in CU (A) and CI (B) individuals. Combination biomarker models with non-binary variable types are compared against a baseline model with binary biomarker definitions (mean performance indicated by dotted line). Colors are used to indicated the variable type of included biomarkers (yellow: binary, purple: non-binary categorical, red: continuous, blue: SVM). Lighter coloring indicates models which only have a single pathology assessment, while darker coloring indicates models which have A $\beta$ , tau, and neurodegeneration biomarkers. Gold stars indicate a significant improvement in accuracy relative to the baseline model (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001). 



231 eFigure 5: Results from experiments predicting the longitudinal change in PHC<sub>Global</sub>. A. 232 Individual and combination biomarker models are compared against a baseline model 233 using only covariates (mean performance indicated by dotted line). **B.** Combination 234 biomarker models with non-binary variable types are compared against a baseline 235 model with binary biomarker definitions (mean performance indicated by dotted line). In both panels, colors are used to indicate the variable type of included biomarkers 236 237 (yellow: binary, purple: non-binary categorical, red: continuous, blue: SVM). Lighter 238 coloring indicates models which only have a single pathology assessment, while darker 239 coloring indicates models which have  $A\beta$ , tau, and neurodegeneration biomarkers. Gold stars indicate a significant improvement in accuracy relative to the topmost model. 240 241 Gray stars and bars highlight significant pairwise differences between individual models. Statistical results are derived from Nadeau-Bengio t-tests with correction for multiple 242 comparisons (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001). 243 244

- 245
- 246
- 247
- 248





250 eFigure 6: Boxplots showing cross-validated accuracy estimates (RMSE) for models 251 predicting neuropsychological performance from biomarkers. Panels show experiments using memory (A), executive functioning (B), language (C), and visuospatial (D) 252 253 composites from the PHC as dependent variables. Combination biomarker models with 254 non-binary variable types are compared against a baseline model with binary biomarker 255 definitions (mean performance indicated by dotted line). In all panels, colors are used 256 to indicate the variable type of included ATN biomarkers (yellow: binary, purple: nonbinary categorical, red: continuous, blue: SVM). Lighter coloring indicates models which 257 258 only have a single pathology assessment, while darker coloring indicates models which 259 have A<sub>β</sub>, tau, and neurodegeneration biomarkers. Gold stars indicate a significant improvement in accuracy relative to the topmost model. 260



263 eFigure 7: Alternate version of main text Figure 1 including CSF predictors alongside264 imaging-based ones.

### 271 eReferences

- Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging β-Amyloid
   Pathology With Amyloid Positron Emission Tomography. *JAMA Neurology*.
   2019;76(11):1319-1329. doi:10.1001/jamaneurol.2019.2214
- Collij LE, Heeman F, Salvadó G, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. *Neurology*. 2020;95(11):e1538-e1553. doi:10.1212/WNL.00000000010256
- Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathol.* 1991;82(4):239-259. doi:10.1007/BF00308809
- Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of
   Alzheimer disease-associated neurofibrillary pathology using paraffin sections and
   immunocytochemistry. *Acta Neuropathol*. 2006;112(4):389-404.
   doi:10.1007/s00401-006-0127-z
- 5. Hsu CW, Chang CC, Lin CJ. A Practical Guide to Support Vector Classification.
   Published online 2003. https://www.csie.ntu.edu.tw/~cjlin/papers/guide/guide.pdf
- 286 6. Haufe S, Meinecke F, Görgen K, et al. On the interpretation of weight vectors of
  287 linear models in multivariate neuroimaging. *NeuroImage*. 2014;87:96-110.
  288 doi:10.1016/j.neuroimage.2013.10.067
- Chen J, Ooi LQR, Tan TWK, et al. Relationship between prediction accuracy and feature importance reliability: An empirical and theoretical study. *Neuroimage*.
   2023;274:120115. doi:10.1016/j.neuroimage.2023.120115
- Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing
   quantitative amyloid plaque estimation by PET. *Alzheimers Dement*. 2015;11(1):1 15.e1-4. doi:10.1016/j.jalz.2014.07.003
- 295 9. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and
  296 longitudinal cognitive decline. *Annals of Neurology*. 2012;72(4):578-586.
  297 doi:10.1002/ana.23650
- 10. Su Y, Flores S, Wang G, et al. Comparison of Pittsburgh compound B and
  florbetapir in cross-sectional and longitudinal studies. *Alzheimers Dement (Amst)*.
  2019;11:180-190. doi:10.1016/j.dadm.2018.12.008
- 301 11. Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut-points for
  302 brain aging and Alzheimer's disease. *Alzheimers Dement*. 2017;13(3):205-216.
  303 doi:10.1016/j.jalz.2016.08.005

- Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to
   hippocampal-mediated beta-amyloid deposition in elderly subjects. *Brain*.
   2009;132(Pt 5):1310-1323. doi:10.1093/brain/awn320
- 307 13. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging
  308 and dementia. *Neurology*. 2009;73(15):1193-1199.
  309 doi:10.1212/WNL.0b013e3181bc010c
- 310 14. Therriault J, Pascoal TA, Lussier FZ, et al. Biomarker modeling of Alzheimer's
  311 disease using PET-based Braak staging. *Nat Aging*. 2022;2(6):526-535.
  312 doi:10.1038/s43587-022-00204-0
- 313 15. Pascoal TA, Therriault J, Benedet AL, et al. 18F-MK-6240 PET for early and late
  314 detection of neurofibrillary tangles. *Brain*. 2020;143(9):2818-2830.
  315 doi:10.1093/brain/awaa180